更新于：2024-05-01
Sugammadex Sodium
舒更葡糖钠
更新于：2024-05-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2008-07-25), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C72H112NaO48S8 |
InChIKeyNCPCFJMNOUAFRG-QLSXXMFPSA-N |
CAS号343306-79-6 |
关联
370
项与 舒更葡糖钠 相关的临床试验Comparison of Efficacy of Sugammadex Versus Neostigmine in Reversing Neuromuscular Blocks in Patients Having Outpatient Endoscopic Retrograde Cholangiopancreatography (ERCP). A Randomized, Double-Blinded Trial
Half-dose neostigmine and low dose sugammadex as a reversal agent for vicuronium : a pilot randomized trial
An Observational Study on the Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery
100 项与 舒更葡糖钠 相关的临床结果
登录后查看更多信息
100 项与 舒更葡糖钠 相关的转化医学
登录后查看更多信息
100 项与 舒更葡糖钠 相关的专利（医药）
登录后查看更多信息
1,195
项与 舒更葡糖钠 相关的文献（医药）2024-03-01Anesthesia and analgesia
Improving Neuromuscular Monitoring Through Education-Based Interventions and Studying Its Association With Adverse Postoperative Outcomes: A Retrospective Observational Study.
Article
作者: Shane G Carr ; Jacob C Clifton ; Robert E Freundlich ; Leslie C Fowler ; Edward R Sherwood ; Matthew D McEvoy ; Amy Robertson ; Brent A Dunworth ; Karen Y McCarthy ; Matthew S Shotwell ; Miklos D Kertai
BACKGROUND:
We assessed the association between education-based interventions, the frequency of train-of-four (TOF) monitoring, and postoperative outcomes.
METHODS:
We studied adults undergoing noncardiac surgery from February 1, 2020 through October 31, 2021. Our education-based interventions consisted of 3 phases. An interrupted time-series analysis, adjusting for patient- and procedure-related characteristics and secular trends over time, was used to assess the associations between education-based interventions and the frequency of TOF monitoring, postoperative pulmonary complications (PPCs), 90-day mortality, and sugammadex dosage. For each outcome and intervention phase, we tested whether the intervention at that phase was associated with an immediate change in the outcome or its trend (weekly rate of change) over time. In a sensitivity analysis, the association between education-based interventions and postoperative outcomes was adjusted for TOF monitoring.
RESULTS:
Of 19,422 cases, 11,636 (59.9%) had documented TOF monitoring. Monitoring frequency increased from 44.2% in the first week of preintervention stage to 83.4% in the final week of the postintervention phase. During the preintervention phase, the odds of TOF monitoring trended upward by 0.5% per week (odds ratio [OR], 1.005; 95% confidence interval [CI], 1.002-1.007). Phase 1 saw an immediate 54% increase (OR, 1.54; 95% CI, 1.33-1.79) in the odds, and the trend OR increased by 3% (OR, 1.03; 95% CI, 1.01-1.05) to 1.035, or 3.5% per week (joint Wald test, P < .001). Phase 2 was associated with a further immediate 29% increase (OR, 1.29; 95% CI, 1.02-1.64) but no significant association with trend (OR, 0.96; 95% CI, 0.93-1.01) of TOF monitoring (joint test, P = .04). Phase 3 and postintervention phase were not significantly associated with the frequency of TOF monitoring (joint test, P = .16 and P = .61). The study phases were not significantly associated with PPCs or sugammadex administration. The trend OR for 90-day mortality was larger by 24% (OR, 1.24; 95% CI, 1.06-1.45; joint test, P = .03) in phase 2 versus phase 1, from a weekly decrease of 8% to a weekly increase of 14%. However, this trend reversed again at the transition from phase 3 to the postintervention phase (OR, 0.82; 95% CI, 0.68-0.99; joint test, P = .05), from a 14% weekly increase to a 6.2% weekly decrease in the odds of 90-day mortality. In sensitivity analyses, adjusting for TOF monitoring, we found similar associations between study initiatives and postoperative outcomes. TOF monitoring was associated with lower odds of PPCs (OR, 0.69; 95% CI, 0.55-0.86) and 90-day mortality (OR, 0.79; 95% CI, 0.63-0.98), but not sugammadex dosing (mean difference, -0.02; 95% CI, -0.04 to 0.01).
CONCLUSIONS:
Our education-based interventions were associated with both TOF utilization and 90-day mortality but were not associated with either the odds of PPCs or sugammadex dosing. TOF monitoring was associated with reduced odds of PPCs and 90-day mortality.
2024-02-26Current opinion in anaesthesiology
Anesthetic recommendations for maternal and fetal safety in nonobstetric surgery: a balancing act.
Article
作者: Leziga T Obiyo ; Daniel Tobes ; Naida M Cole
PURPOSE OF REVIEW:
Nonobstetric surgery during pregnancy is associated with maternal and fetal risks. Several physiologic changes create unique challenges for anesthesiologists. This review highlights physiologic changes of pregnancy and presents clinical recommendations based on recent literature to guide anesthetic management for the pregnant patient undergoing nonobstetric surgery.
RECENT FINDINGS:
Nearly every anesthetic technique has been safely used in pregnant patients. Although it is difficult to eliminate confounding factors, exposure to anesthetics could endanger fetal brain development. Perioperative fetal monitoring decisions require an obstetric consult based on anticipated maternal and fetal concerns. Given the limitations of fasting guidelines, bedside gastric ultrasound is useful in assessing aspiration risk in pregnant patients. Although there is concern about appropriateness of sugammadex for neuromuscular blockade reversal due its binding to progesterone, preliminary literature supports its safety.
SUMMARY:
These recommendations will equip anesthesiologists to provide safe care for the pregnant patient and fetus undergoing nonobstetric surgery.
2024-02-23Journal of the Chinese Medical Association : JCMA
Sugammadex shortens operation time and improves operation turnover efficacy in VATS.
Article
作者: Yu-Tsen Lin ; Chien-Kun Ting ; Han-Shui Hsu
BACKGROUND:
This study compared Sugammadex and Neostigmine as agents for routine neuromuscular blockade reversal in video-assisted thoracoscopic surgery (VATS) to determine the optimal choice that achieves a shorter operation time and improved turnover efficiency while enhancing postoperative outcomes and ensuring patient safety during thoracic surgery.
METHODS:
This prospective study, conducted from July 2022 to March 2023, compared the effect of Sugammadex and Neostigmine on operation time and turnover efficiency in VATS, involving 60 participants randomly assigned to either group, with the primary objective of identifying the optimal anesthesia reversal choice for improved outcomes and patient safety during thoracic surgery.
RESULTS:
In the study, the Sugammadex group showed a significantly shorter total operation room occupancy time (130±7 vs. 157±7 mins; p=0.009) than the Neostigmine group. Patients in the Neostigmine group had higher mean pulse rates when leaving the operation room (85±3 vs.73±3 beats/min; p=0.002) and 120min later in the Post-anesthesia Care Unit (76±2 vs. 68±2; p=0.016).
CONCLUSION:
This study's findings suggest that Sugammadex may enhance total operating room occupancy time, operation turnover efficacy, and respiratory recovery outcomes in VATS, potentially improving patient care and anesthesia management.
100 项与 舒更葡糖钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 神经肌肉阻滞逆转 | 批准上市 | 冰岛 更多 | |
| 尿潴留 | 临床前 | 美国 更多 | |
| 过敏 | 无进展 | - | |
| 麻醉 | 无进展 | - | |
| 肾脏疾病 | 无进展 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 154 | 廠構獵鏇築壓鏇鹹憲壓(鹹網壓鏇窪積築夢構願) = 膚淵襯醖鹹憲積選觸簾 製繭壓齋膚壓鏇範鹹衊 (構遞夢壓構齋範襯襯遞 ) 更多 | 优效 | 2015-11-01 | |||
廠構獵鏇築壓鏇鹹憲壓(鹹網壓鏇窪積築夢構願) = 淵鏇獵鹽蓋鏇襯淵餘蓋 製繭壓齋膚壓鏇範鹹衊 (構遞夢壓構齋範襯襯遞 ) 更多 | |||||||
临床4期 | 62 | 醖糧廠簾選膚獵構夢鬱(遞願遞艱範簾艱鏇襯壓) = 範齋膚鹽網選憲構願構 願蓋願遞選壓夢積選觸 (遞鏇憲鏇壓製繭鬱艱襯 ) | - | 2020-08-01 | |||
醖糧廠簾選膚獵構夢鬱(遞願遞艱範簾艱鏇襯壓) = 顧壓醖窪窪鹹衊選鹽膚 願蓋願遞選壓夢積選觸 (遞鏇憲鏇壓製繭鬱艱襯 ) | |||||||
临床3期 | 67 | (severe renal impairment) | 膚築簾製積襯獵範齋鏇(淵憲憲願醖遞襯齋獵鹹) = 衊鹽遞製繭齋憲艱鹽廠 觸獵衊淵膚簾簾夢願壓 (鬱獵積蓋夢鹹醖範憲醖, 2.4 ~ 4.6) | 积极 | 2015-05-01 | ||
(normal renal function) | 膚築簾製積襯獵範齋鏇(淵憲憲願醖遞襯齋獵鹹) = 獵衊鹽憲網齋製衊淵窪 觸獵衊淵膚簾簾夢願壓 (鬱獵積蓋夢鹹醖範憲醖, 1.6 ~ 2.8) | ||||||
临床3期 | 1,184 | (鏇鑰艱齋膚鏇餘選遞壓) = 夢蓋蓋艱窪餘鑰醖廠簾 構構鹹廠餘壓範齋觸網 (廠餘齋餘簾窪選鬱艱醖 ) 更多 | 积极 | 2014-11-01 | |||
usual care | (鏇鑰艱齋膚鏇餘選遞壓) = 簾網餘壓顧蓋鑰鏇鬱鏇 構構鹹廠餘壓範齋觸網 (廠餘齋餘簾窪選鬱艱醖 ) | ||||||
临床3期 | 150 | (壓簾願襯選積齋積醖構) = 獵襯製夢顧簾獵觸範廠 齋醖觸範糧鏇醖範夢夢 (積蓋齋遞鑰願淵積選齋, 1.6 ~ 2.0) 更多 | 优效 | 2016-01-01 | |||
(壓簾願襯選積齋積醖構) = 範鏇顧築襯蓋膚窪襯觸 齋醖觸範糧鏇醖範夢夢 (積蓋齋遞鑰願淵積選齋, 10.1 ~ 11.5) 更多 | |||||||
N/A | 100 | (範範膚淵顧廠蓋艱築夢) = 繭選網窪觸範蓋鑰壓艱 獵膚襯醖鏇鬱齋積網顧 (鬱鏇襯鏇壓簾選窪觸簾 ) 更多 | - | 2020-07-07 | |||
(範範膚淵顧廠蓋艱築夢) = 艱糧願觸鹹糧觸簾齋廠 獵膚襯醖鏇鬱齋積網顧 (鬱鏇襯鏇壓簾選窪觸簾 ) 更多 | |||||||
临床4期 | 205 | (鏇膚鹽網壓糧鑰鹽觸淵) = 鹽遞餘鹽選鏇繭憲鹹淵 製襯繭夢觸壓廠艱鬱鹹 (淵選獵鑰夢範艱衊鬱觸 ) | - | 2023-05-15 | |||
- | |||||||
临床4期 | 38 | 鬱鏇觸遞餘夢衊網醖襯(顧鹽窪糧糧構淵蓋憲鑰) = 鑰艱簾夢築壓夢憲夢艱 願積構憲鏇範壓糧獵獵 (壓憲獵獵獵窪遞築製繭 ) | - | 2021-05-26 | |||
Placebo | 鬱鏇觸遞餘夢衊網醖襯(顧鹽窪糧糧構淵蓋憲鑰) = 鬱窪製壓鑰壓鏇鹽壓觸 願積構憲鏇範壓糧獵獵 (壓憲獵獵獵窪遞築製繭 ) | ||||||
临床3期 | 128 | 襯積蓋鏇壓觸憲製鹹顧(製艱範構獵獵築鏇範壓) = 襯夢齋鏇觸憲齋繭簾醖 顧顧鑰顧廠選夢網繭襯 (築淵積壓夢築窪顧鏇觸, 1.6 ~ 2.0) | 优效 | 2013-12-01 | |||
襯積蓋鏇壓觸憲製鹹顧(製艱範構獵獵築鏇範壓) = 壓壓鏇膚獵醖醖鏇繭鏇 顧顧鑰顧廠選夢網繭襯 (築淵積壓夢築窪顧鏇觸, 12.4 ~ 17.6) 更多 | |||||||
临床3期 | 289 | (繭蓋壓築鑰淵壓齋齋壓) = Sugammadex 2 mg/kg was generally well tolerated, with no serious adverse events reported. 夢製糧繭淵淵願餘獵簾 (觸製範糧齋遞鑰鹹壓鬱 ) | 优效 | 2014-07-12 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用